 "Glenmark Pharma: Acid reflux capsules get US FDA nod, shares rise")
Glenmark Pharmaceuticals on Tuesday said it has received final approval from the US health regulator for generic version of AstraZeneca's Nexium, used to treat acid reflux.
Glenmark Pharmaceuticals Inc, USA, has been granted final approval by the United States Food & Drug Administration (US FDA) for Esomeprazole Magnesium delayed-release capsules USP in the strengths of 20 mg and 40 mg, the company said in a BSE filing.
The approved products is a generic version of AstraZeneca Pharmaceuticals' Nexium delayed-release capsules.
Citing IQVIA sales data, Glenmark said, Nexium delayed-release capsules, 20 mg and 40 mg achieved annual sales of around $395.1 million in the 12-month period ended March 2019.
The company said its current portfolio consists of 153 products authorised for distribution in the US and 58 Abbreviated New Drug Applications (ANDA) pending approval with the US FDA.
Shares of Glenmark Pharma were trading 0.46 per cent higher at Rs 594.35 apiece on BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%